The University of Chicago Header Logo

Connection

Daniel Arber to Myelodysplastic Syndromes

Back to Details
This is a "connection" page, showing publications Daniel Arber has written about Myelodysplastic Syndromes.
Daniel Arber
Connection Strength
8.612
Myelodysplastic Syndromes
  1. Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future. Am J Hematol. 2025 Jun; 100 Suppl 4:5-15.
    View in: PubMed
    Score: 0.693
  2. The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Adv Anat Pathol. 2025 Jul 01; 32(4):299-306.
    View in: PubMed
    Score: 0.689
  3. Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia. Am J Hematol. 2023 03; 98(3):377-378.
    View in: PubMed
    Score: 0.595
  4. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023 Jan; 482(1):27-37.
    View in: PubMed
    Score: 0.588
  5. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
    View in: PubMed
    Score: 0.513
  6. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? Best Pract Res Clin Haematol. 2020 06; 33(2):101139.
    View in: PubMed
    Score: 0.483
  7. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol. 2016 09; 29(9):996-1003.
    View in: PubMed
    Score: 0.378
  8. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
    View in: PubMed
    Score: 0.374
  9. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015; 2015:294-8.
    View in: PubMed
    Score: 0.342
  10. Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol. 2014 Aug; 142(2):190-5.
    View in: PubMed
    Score: 0.332
  11. E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol. 2014 May; 141(5):656-64.
    View in: PubMed
    Score: 0.327
  12. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009 Feb 26; 113(9):1906-8.
    View in: PubMed
    Score: 0.226
  13. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
    View in: PubMed
    Score: 0.183
  14. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
    View in: PubMed
    Score: 0.179
  15. Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
    View in: PubMed
    Score: 0.177
  16. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May 29; 145(22):2561-2573.
    View in: PubMed
    Score: 0.176
  17. TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
    View in: PubMed
    Score: 0.173
  18. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 08 01; 109(8):2525-2532.
    View in: PubMed
    Score: 0.166
  19. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204(4):1243-1248.
    View in: PubMed
    Score: 0.159
  20. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Hum Pathol. 2003 Aug; 34(8):809-13.
    View in: PubMed
    Score: 0.155
  21. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leuk Res. 2023 07; 130:107309.
    View in: PubMed
    Score: 0.153
  22. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 04; 98(4):E76-E79.
    View in: PubMed
    Score: 0.150
  23. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022 Oct; 481(4):621-646.
    View in: PubMed
    Score: 0.144
  24. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022 05 10; 6(9):2847-2853.
    View in: PubMed
    Score: 0.142
  25. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations. Am J Clin Pathol. 2002 Feb; 117(2):306-13.
    View in: PubMed
    Score: 0.140
  26. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion. 2020 08; 60(8):1867-1872.
    View in: PubMed
    Score: 0.126
  27. Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017 Jul 01; 148(1):49-57.
    View in: PubMed
    Score: 0.102
  28. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997 Apr; 107(4):430-7.
    View in: PubMed
    Score: 0.100
  29. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017 03; 30(3):382-392.
    View in: PubMed
    Score: 0.098
  30. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.
    View in: PubMed
    Score: 0.081
  31. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica. 2014 May; 99(5):821-9.
    View in: PubMed
    Score: 0.080
  32. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013 Feb 19; 110(8):3011-6.
    View in: PubMed
    Score: 0.075
  33. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol. 2009 Jun; 146(1):86-90.
    View in: PubMed
    Score: 0.058
  34. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
    View in: PubMed
    Score: 0.058
  35. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
    View in: PubMed
    Score: 0.041
  36. Primary myelodysplasia occurring in adults under 50 years old: a clinicopathologic study of 52 patients. Leukemia. 2002 Apr; 16(4):623-31.
    View in: PubMed
    Score: 0.035
  37. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000 Mar 01; 95(5):1588-93.
    View in: PubMed
    Score: 0.031
  38. Untreated chronic lymphocytic leukemia concurrent with or followed by acute myelogenous leukemia or myelodysplastic syndrome. A report of five cases and review of the literature. Am J Clin Pathol. 1999 Mar; 111(3):373-8.
    View in: PubMed
    Score: 0.029
  39. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
    View in: PubMed
    Score: 0.025
  40. Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience. Am J Clin Pathol. 2013 Jun; 139(6):818-25.
    View in: PubMed
    Score: 0.019
  41. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol. 2010 Aug; 85(8):600-6.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.